NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Ocugen, Inc. (OCGN) Stock Analysis

Ocugen, Inc. (OCGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

OCGN

$1.36

+$0.01 (+0.74%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OCGN with… →

OCGN Key Statistics

As of Sep 4, 2026
Trading
Open
$1.32
Previous Close
$1.35
Day's Range
1.31–1.38
52-Week Range
1.01–2.73
Volume
3.56M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.21
Valuation
Market Cap
$461.19M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
100.67
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.26
Financials (FY)
Revenue (FY)
$4.41M+8.83%
Net Income (FY)
−$67.85M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
339.11M
1-Year Return
+32.04%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
6.11M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OCGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.74%
2025+67.70%
2024+40.00%
2023−55.77%
2022−71.43%
2021+148.63%
2020+251.92%
2019−90.15%
2018−95.71%
2017+22.75%
2016 (partial year)−18.54%

As of September 4, 2026.

OCGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.41M−$67.85M−1537.4%
2024$4.06M−$54.05M−1333.0%
2023$6.04M−$63.08M−1045.0%
2022$2.49M−$86.80M−3488.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.41M—−$62.92M−$67.85M−1537.4%
2024$4.06M—−$54.76M−$54.05M−1333.0%
2023$6.04M—−$65.53M−$63.08M−1045.0%
2022$2.49M—−$89.07M−$86.80M−3488.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OCGN Valuation vs Biotechnology Median

Median of 656 stocks
MetricOCGNBiotechnology medianvs median
P/S ratio100.6715.266.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Ocugen, Inc. (OCGN) is capitalised at $461.19M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 116 employees.

The 52-week range on file runs from $1.01 to $2.73. The most recent close on file for OCGN is $1.36, dated September 4, 2026. That is +$0.01 (+0.74%) against the previous close. The latest close sits 34.65% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $4.41M. That is +8.83% against the prior fiscal year, when revenue was $4.06M. The same year closed with a net loss of $67.85M. Profit margin runs at 0%. Trailing earnings per share are −0.26.

Across the 4 fiscal years on file, revenue moves from $2.49M in 2022 to $4.41M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 100.67. On price-to-sales that is 6.6 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +32.04%. Measured over 10 years, that is −39.19% a year compounded. The reported beta is 2.21. Annualized volatility over the trailing 10 years is 165.87%.

Growth & Income

No dividend is on file for OCGN.

2026 is still running; the price is +0.74% year to date. Across the complete calendar years on file, 2020 returned +251.92% and 2018 returned −95.71%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Ocugen, Inc. (OCGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ocugen, Inc. OCGN $461.19M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Ocugen, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Ocugen, Inc.

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Visit website →